Breast cancer Cancer Malignant neoplasm of breast
Conditions
Interventions
Randomisation into a research or control arm:
Group A: attend pharmacy outpatient clinic
Group B: usual care
Sponsors
Record Provided by the NHSTCT Register - 2005 Update - Department of Health (UK)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. 140 patients being treated for breast cancer and receiving chemotherapy. 2. 18 years and above
Exclusion criteria
Exclusion criteria: Does not match inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Level of patient understanding: The chief investigator (HR) interviewed each consented patient using a standard question set, asking the patient to explain what each of their support medications was for and how they used it. Assessments were recorded as an overall rating of the subject's understanding on a Likert scale from 1=very poor to 5=very good, plus a drug-specific score derived from marks awarded for various pieces of information: drug name (+2); indication (+2); dose frequency (+2); dose duration (+1); dose (+1). Thus the maximum score per drug was 8 and the minimum 0. The average score per drug was also calculated. Assessments were conducted prior to randomisation; the chief investigator was blind during subsequent, post-randomisation assessments. | — |
Secondary
| Measure | Time frame |
|---|---|
| Added 16/09/10: 1. The numbers of patients experiencing delays in receiving their chemotherapy 2. The numbers of patients requiring chemotherapy dose reductions 3. Numbers of patients having potential drug interactions between GP prescribed medication and chemotherapy or chemotherapy support medication 4. The number of chemotherapy support medication items supplied per patient 5. The average cost of chemotherapy support medication supplied per patient 6. The numbers and costs of chemotherapy support medication not supplied 7. The average amount of pharmacy time per patient spent resolving medication issues 8. The numbers of patients requiring a prescription intervention at the point of dispensing | — |
Countries
United Kingdom
Outcome results
None listed